Skip to content
Review

Primary Pulmonary NUT Carcinoma: Genomic Landscape, Diagnostic Challenges, Molecular Pathogenesis, and the Evolving Role of Radiotherapy, Targeted Therapies, and Immunotherapy.

Nov 2026 · Critical reviews in oncology/hematology · pp. 105700 · 0 citations · 119 references
Medicine

Abstract

Primary pulmonary NUT carcinoma (PPNC) is an ultra-rare, highly aggressive thoracic malignancy driven by NUTM1 rearrangements, most commonly BRD4:NUTM1. Morphologic overlap with poorly differentiated squamous cell carcinoma, neuroendocrine carcinoma, and carcinoma not otherwise specified frequently delays diagnosis, while rapid progression and limited evidence hinder treatment standardization. This narrative review synthesizes literature identified through PubMed/MEDLINE and Web of Science, together with registered trials from ClinicalTrials.gov, through May 2026, covering epidemiology, molecular pathogenesis, diagnosis, locoregional therapy, systemic treatment, and investigational strategies. An exploratory descriptive analysis of 15,938 lung tumor samples from 41 independent cBioPortal datasets identified a canonical NUTM1 structural variant in 1 of 15,938 samples (0.006%), supporting the genomic rarity of PPNC and highlighting potential limitations of DNA-only workflows for clinically relevant rearrangements. PPNC is usually reported in young to middle-aged adults, appears more frequent in men, and commonly presents with nonspecific thoracic symptoms. Molecular data suggest phenotypic and transcriptional convergence with squamous cell carcinoma through BRD-NUT-driven programs centered on MYC and TP63, with context-dependent SOX2 activation. Accurate recognition requires early NUT immunohistochemistry, followed when feasible by RNA-based fusion testing. No standard systemic regimen exists. Platinum-based regimens remain common, whereas retrospective pulmonary-specific data suggest that definitive chemoradiotherapy may be preferable to chemotherapy alone in selected patients. Bromodomain and extraterminal (BET) inhibitor monotherapy shows target engagement but limited durability, supporting rational combinations. Radiotherapy-immunotherapy combinations and PRAME-directed T-cell-engaging therapies remain investigational; the latter have only preclinical support so far. Earlier diagnosis, multimodal definitive treatment, and prioritized basket-trial enrollment are essential to improve outcomes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.